A Double-Blind, Phase 1, Single-Center, Single-Ascending Dose Study of JZP-386 Compared to Xyrem® vs. Placebo to Evaluate the Safety and Pharmacokinetics
Phase of Trial: Phase I
Latest Information Update: 09 Jun 2015
Price : $35 *
At a glance
- Drugs Sodium oxybate deuterated (Primary) ; Sodium oxybate
- Indications Narcolepsy
- Focus Adverse reactions; First in man
- Sponsors Concert Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 09 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 28 Aug 2014 According to the ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.